Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy

AIDS

Volumn 14, Issue 8, 2000, Pages 1041-1049

  Salmon Céron, Dominique ^c   Mazeron, Marie Christine ^d   Chaput, Sophie ^d   Boukli, Norjis ^d   Senechal, Brigitte ^d   Houhou, Nadira ^d   Katlama, Christine ^d   Matheron, Sophie ^d   Fillet, Anne Marie ^d   Gozlan, Joël ^d   Leport, Catherine ^d   Jeantils, Vincent ^d   Freymuth, François ^a   Costagliola, Dominique ^b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c Hôpital COCHIN ^*  (France)

^d NONE

Author keywords

CD4; CMV; CMV disease; HAART; Highly active antiretroviral therapy; HIV; Plasma cytomegalovirus DNA; Prognostic factors of disease

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; MESSENGER RNA; PROTEINASE INHIBITOR; VIRUS ANTIGEN; VIRUS DNA;

ADULT; ARTICLE; CLINICAL TRIAL; COVARIANCE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; VIRUS LOAD;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MIDDLE AGED; PHOSPHOPROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 0000027197     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005260-00017     Document Type: Article

References (18)

1. 1. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease, Lancet 1998, 351:1682-1686.
2. 2. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
3. 3. Komanduri KV, Viswanathan MN et al. Restoration of cytomegalovirus-specific CD4 T-lymphocyte responses after ganci-clovir and highly active antiretroviral therapy (HAART) in individuals infected with HIV-1. Nat Med 1998, 4:953-956.
4. 4. Costagliola D for the Clinical Epidemiology Group from CISIH. Trends in incidence of clinical manifestations of HIV infection and antiretroviral prescriptions in French University Hospitals. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February, 1998 [Abstract 1182].
5. 5. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998, 351:228-230.
6. 6. Jacobson MA, Zegans M, Pavan PR et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997, 349:1443-1445.
7. b/l following combination antiretroviral therapy including protease inhibitors. AIDS 1997, 11:1659-1660.
8. 8. Gérard L, Leport C, Flandre P et al. Cytomegalovirus (CMV) viremia and the CD4+ lymphocytes count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis 1997, 24: 836-840.
9. 9. Gallant JE, Moore RD, Richman D et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Iinfect Dis 1992, 166:1233-1227.
10. 10. Salmon-Céron D, Fillet AM, Aboulker JP and ANRS 023 study group. Effect of a 14-day course of foscarnet on CMV blood markers in a randomized study of HIV-infected patients with persistent CMV viremia. Clin Infect Dis 1999, 28:901-905.
11. 11. Shinkai M, Bozette SA, Powderly W, Frame P, Spector SA. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk of developing human cytomegalovirus disease. J Infect. Dis 1997, 175:302-308.
12. 12. Boivin G, Hanfield J, Toma E, Murray G, Lalonde R, Bergeron MG. Comparative evaluation of the cytomegalovirus DNA load in polymorphonuclear leukocytes and plasma of human immunodeficiency virus-infected subjects. J Infect Dis 1998, 177: 335-360.
13. 13. Gozlan J, Salord J.M, Chouaid C et al. Human cytomegalovirus (HCMV) late mRNA detection in peripheral blood of AIDS patients: diagnostic value for HCMV disease compared with those of viral culture and HCMV DNA detection. J Clin Microbiol 1993, 31:1943-1945.
14. 14. Matheron S, Chaput S, Gerbe J et al. Effect of protease inhibitors on the incidence of CMV retinitis in HIV-infected patients. Sixth European Conference on Clinical Aspects and Treatment of HIV infection. Hambourg, 1997 [Abstract 2321].
15. 15. Baril L, Jouan M, Rachid A et al. Impact of new multidrug therapy containing a protease inhibitor on the occurrence of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [Abstract 130-131].
16. 16. Arrizabalaga J, Casado JL, Tural C et al. Incidence and risk factors for developing CMV retinitis in HIV-infected patients receiving protease inhibitor therapy. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, 1999 [Abstract 251].
17. 17. Torriani FJ, Freeman WR, Karavellas M et al. Lymphoproliferative responses to CMV predict CMV retinitis reactivation in patients who discontinued. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, 1999 [Abstract 250].
18. 18. Chevret S, Scieux C, Garrault V et al. Usefulness of the cytomegalovirus antigenemia assay for predicting the occurrence of CMV disease and death in patients with AIDS. Clin Infect Dis 1999, 28:758-763.